Summary
Mice infected intravenously with vaccinia virus develop characteristic lesions over
the entire tail surface. This experimental virus infection presents a highly
sensitive and reliable model for evaluating the antivaccinia activity of antiviral
compounds. Ara-C (1 -β-D-arabinofuranosylcytosine), ribavirin
(1-β-D-ribofuranosyl-1,2,4-tria-zole-3-carboxamide), IUdR (5-iodo-2′-deoxyuridine) as
well as two novel analogs of IUdR, EtUdR (5-ethyl-2′-deoxyuridine), and NCSUdR
(5-thiocyanato-2′-deoxyuri-dine), were found to inhibit the formation of vaccinia
tail lesions, when administered in-traperitoneally once daily for 7 days starting
immediately after virus infection. The order of (decreasing) activity was: ara-C >
IUdR > NCSUdR > ribavirin > EtUdR. Various drug combinations, involving IUdR
+ ara-C, NCSUdR + ara-C, NCSUdR + IUdR, NCSUdR + ribavirin, etc., were evaluated, but
none proved more efficacious than either compound administered alone.
This investigation was supported by grants from the F.G.W.O. (Fonds voor Geneeskundig
Wetenschappel-ijk Onderzoek) and the K.U.L. (Katholieke Universi-teit Leuven) “Fonds
Derde Cyclus.” M. L. was supported by a postdoctoral fellowship of the K.U.L. “Fonds
Derde Cyclus.” We thank Dr. H. A. Jolley (Cyanamid International Co., Pearl River,
New York) and Dr. F. Dehaen (Cyanamid Benelux, Lederle Laboratories Division,
Brussels) for the generous supply of ribavirin.